DR. MADHU V MIDATHADA MD NPI 1265511034

NPI Details

DR. Madhu V Midathada, MD is a hematology and oncology internal medicine in Lincoln, NE with 34 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Madhu V Midathada, MD NPI is 1265511034. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

4004 PIONEER WOODS DR
LINCOLN, NE
ZIP 68506-548
Phone: (402) 484-4900
Fax: (402) 484-6456

The NPI 1265511034 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Uric acid level, blood (HCPCS:84550)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Ferritin (blood protein) level (HCPCS:82728)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Creatine kinase (cardiac enzyme) level, total (HCPCS:82550)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Magnesium level (HCPCS:83735)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Chemical receptor analysis (HCPCS:84238)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Red blood count, automated test (HCPCS:85045)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Administration of prolonged chemotherapy into vein (HCPCS:96416)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Blood test, clotting time (HCPCS:85610)
• Vitamin d-3 level (HCPCS:82306)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Injection of drug or substance into vein (HCPCS:96374)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Cortisol (hormone) measurement, total (HCPCS:82533)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Amylase (enzyme) level (HCPCS:82150)
• Lipase (fat enzyme) level (HCPCS:83690)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Folic acid level, serum (HCPCS:82746)
• Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free (HCPCS:90674)
• Administration of influenza virus vaccine (HCPCS:G0008)

The enumeration date for this NPI number is 11/3/2006 and was last updated on 5/1/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: